Resverlogix Corp (RVXCF) 1.3698 $RVXCF Resverlogix

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Resverlogix Corp (RVXCF) 1.3698 $RVXCF

Resverlogix Announces Voting Results
PR Newswire - Wed Sep 30, 3:46PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Resverlogix Provides Research and Development Update in New York City
PR Newswire - Tue Sep 29, 6:30AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
PR Newswire - Thu Sep 24, 6:00AM CDT
Apabetalone (RVX-208) to be tested in a proof-of-concept pilot trial in a complement mediated disease Paroxysmal Nocturnal Hemoglobinuria (PNH) in 2016
RVX.TO: 1.76 (-0.04)

Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
PR Newswire - Thu Sep 10, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company" (TSX:RVX) is pleased to announce that Mr. Donald McCaffrey, president and chief executive officer of Resverlogix Corp. will be presenting today at the Rodman & Renshaw 17th Annual Global Investment Conference at 10:25 am EDT in Louis XVI A (2nd floor, St. Regis Hotel, New York). The presentation will be available via webcast at: http://wsw.com/webcast/rrshq25/rvxhttp://wsw....rshq25/rvx
RVX.TO: 1.76 (-0.04)

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
PR Newswire - Tue Aug 04, 6:30AM CDT
Professor Kausik Ray to Chair Clinical Steering Committee for Landmark Epigenetic BET Inhibition Trial
RVX.TO: 1.76 (-0.04)

Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 2.52 (+0.08), KNMD: (), VTAE: 13.00 (+0.10), LLY: 86.14 (+2.37), OMER: 12.66 (+0.58), JNJ: 95.37 (+0.29), ISIS: 43.24 (+0.86), OPK: 8.90 (+0.26), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), VBLT: 7.35 (-0.23), NVS: 91.90 (-0.71)

Shenzhen Hepalink Pharmaceutical Co., Ltd. Announces Investment in Resverlogix Corp.
Marketwired - Fri Jul 24, 11:21AM CDT
Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink" is pleased to announce that on July 20, 2015, Hepalink acquired 13,270,000 units ("Units" of Resverlogix Corp. ("RVX" by way of a private placement (the "Private Placement" at a price of Cdn.$2.67 per Unit, for an aggregate purchase price of Cdn.$35,430,900. Each Unit consists of one common share of RVX ("Common Share" plus 0.075358 of a common share purchase warrant of RVX ("Warrant" expiring five years after the closing of the Private Placement. Each whole Warrant entitles Hepalink to purchase one Common Share at an exercise price of Cdn.$2.67. The Private Placement was part of a larger offering of Units pursuant to which RVX issued 18,870,000 Units for aggregate proceeds of Cdn$50,382,900 (the "Offering" .

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63tfvw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - KunWha Pharmaceutical Co., Ltd. - MedImmune, LLC - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. Drug Profiles - (cilostazol organic nitrate) ER - AEM-28 - ALD-301 - Annexin A-5 - CVBT-141C - DVC1-0101 - ELS-140 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - MEDI-6012 - Mesenchymal Stem Cells - MGN-6114 - MultiGeneAngio - MultiGeneGraft - MultiStem - O-304 - PDA-002 - REC-03 - rivaroxaban - RVX-208 - sarpogrelate SR - selegiline Antiplatelet Drugs - sodium nitrite SR - Stem Cell Therapy for Cardiovascular Diseases - SYN-20112312RU - ticagrelor - transcrocetinate sodium - TXA-127 - VM-202 - vonapanitase For more information visit http://www.researchandmarkets.com/research/63tfvw/peripheral
AZN: 32.23 (-0.16), ATHX: 1.14 (-0.01), PRTO: 14.52 (+0.30), CELGZ: 1.74 (+0.04)

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
PR Newswire Europe - Tue Jul 21, 8:12AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 8.90 (+0.26), ICPT: 181.90 (-8.81), LLY: 86.14 (+2.37), CNCE: 20.87 (+0.62), XLRN: 24.08 (-0.18)

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
PR Newswire - Wed Jul 08, 6:00AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
PR Newswire - Tue Jun 30, 4:39PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Resverlogix to Present at the 2015 Bio International Convention
PR Newswire - Wed Jun 17, 6:30AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
PR Newswire - Mon Jun 08, 10:35AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.76 (-0.04)

Restenosis Pipeline Review 2015 - 7 Companies & 14 Drug Profiles
M2 - Thu May 21, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xq5hhl/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - CSPC Pharmaceutical Group Limited - CytoTools AG - Resverlogix Corp. - Shire Plc - Viron Therapeutics, Inc. - XBiotech USA, Inc. Drug Profiles - Annexin A-5 - Antibody Conjugate for Restenosis - butylphthalide - COR-3 - CV-18C3 - HMW-02Ak - HMW-02Ap - HO-3867 - LDH-DDART - PVS-10200 - Small Molecules for Cardiovascular Diseases - Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - VAN 10-4 - VT-214 For more information visit http://www.researchandmarkets.com/research/xq5hhl/restenosis
SHPG: 200.90 (-1.85)

Week In Review: WuXi PharmaTech Announces $3.3 Billion Go-Private Offer
ChinaBio Today - at Seeking Alpha - Sun May 03, 4:57AM CDT
Deals and Financings WuXi PharmaTech (NYSE: WX ), China's largest CRO/CMO, announced a surprise privatization offer of $46 per ADS from Dr. Ge Li, the company's founder, chairman and CEO, and Ally Bridge Group Capital Partners. Before the offer,...
CO: 6.23 (-0.01), WX: 44.15 (+0.04)

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
CNW Group - Mon Apr 27, 6:00AM CDT
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million
RVX.TO: 1.76 (-0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 10

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 111

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 49

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 19

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 0

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 75

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 162

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles